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inhalation productsDear editor,
I read the article with interest by Brashier et al.1 that was
published in the December 2007 edition of Respiratory
Medicine. This study compared the currently available
Tiotropium Dry Powder Inhaler (DPI) (Rotahaler&) and a
new pressurized metered dose inhaler (pMDI) plus spacer
(Zerostat, Cipla Ltd.). This study demonstrates that tiotro-
pium administered by pMDI and spacer shows a superior
time-dependent bronchodilator response when compared to
placebo in moderate-to-severe COPD patients. This demon-
stration of superiority to placebo shows efficacy, which is
important not only because some patients are hypotheti-
cally not able to inhale with enough peak inspiratory flow
rate, but because the pMDI products are much cheaper and
increase the affordability of inhaled medicines not only in
developed countries but especially in developing countries.
Please note that all participants of the study had not
received in the past any inhaled therapy and were being
treated with oral theophylline and oral salbutamol.
The authors also concluded a similar therapeutic efficacy
with both devices based on this randomized, double blind,
double dummy, single dose (18mcg), three period, placebo-
controlled cross-over study. However, from my point of view,
the study design does not allow a valid comparison between
both active treatments and, therefore, the conclusions
regarding its similarity might be inaccurate.
It is essential to take into account that the comparison of
two bronchodilating agents or products should have been
performed with at least two doses of each agent/product to
calculate a rudimentary dose response curve for each
agent/product,2 which indicates if the study presents assay
sensitivity to detect differences between these two agents/
products. Unfortunately, we frequently observe in these
studies that one actuation and two actuations of a given
device provide a very similar response due to flatness of the
dose–response curve of all these drugs.3 Therefore, the
apparent similarity in response obtained in this study could
be caused by the flatness of the dose–response curve4 in
spite of the fact that one of the devices might deliver a
much larger amount of drug to the lung receptors.5
To solve this sensitivity problem, it was proposed in the past
that the comparison should not be based on the responseont matter & 2007 Elsevier Ltd. All rights reserved.
2007.12.015obtained in the Y-axis with equivalent doses of each agent/
product, but on the shift of the dose–response curve in the
X-axis of both agents/products, which is called the relative
potency or potency ratio.6 This concept was applied to the
comparison of inhalation products more than 30 years ago7–9
and has been incorporated into the requirements of the
Regulatory Agencies to avoid false conclusions of equivalence
due to the flatness of the dose–response curve of
b2-agonists.
10–12 Unfortunately, this methodology has not
been followed in most of the comparative trials that can be
found in the literature.13 Single-dose studies comparing only
one dose,1 or cumulative-dose studies14 are the rule, although
they are known to be inadequate due to their insensitivity.2,15
The design of this trial could have shown to be sensitive if
at least an additional treatment of 36mcg of tiotropium
with any of these two products had been included, although
it is preferable to test 18 and 36mcg with both devices to
calculate the relative potency.
It is also important to highlight that the primary variable
should be the area under the response curve for FEV1 over a
period of 24 h since the peak or maximum effect is much less
sensitive to detect the differences between agent/products
due to the ceiling effect. However, it is well known that the
greater the dose, the larger the duration of action and the
AUC of the response–time curve.3 This is also shown in this
study since the difference in mean maximum change from
the baseline for FEV1 was a 12% and for FVC was 1%. In
contrast, the mean difference of AUC for percent change in
FEV1 was a 59% and in FVC was 25%. Similarly, the larger
difference in inspiratory capacity (30%) between both active
treatments was observed at 24 h.
The inability of this study to detect a 59% difference in
FEV1 AUC suggests that the study was not powered to detect
relevant differences in the Y-axis, even assuming that a
comparison in the Y-axis were methodologically correct.
The sample size calculation seems to be based on the
maximum FEV1. The acceptance range (7100mL) is appar-
ently similar to the difference between the reference
product and placebo, according to Figure 4 of Brashier
et al.’s paper, which is unacceptable because a product similar
to placebo could be considered as equivalent. In addition, this
large difference in FEV1 AUC (59%) suggests that one of the
devices delivers much more drug to the lung receptors than
the other. According to Figure 2 of Brashier et al.’s paper, the
new pMDI seems to be more potent, but the text of the paper
indicates the contrary: ‘‘FEV1 AUC024h: 997 versus 1589 for
pMDI plus spacer and DPI, respectively; p40.05’’.
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based on an equivalence hypothesis because the expected
difference between test and reference is not stated and the
95% CI have not been provided in the paper. Therefore, it
seems to be a superiority hypothesis and the authors
conclude equivalence because they are not able to find
statistical significant differences based in a very permissive
delta value of 100mL. It has to be remembered again that
the inability to reject the null hypothesis does not support
the validity of the null hypothesis.
In conclusion, as further studies are apparently planned,
it would be convenient for the development of this product
and its regulatory acceptance that the authors conduct a
new single-dose study, in a bronchodilation or a broncho-
provocation model,12,16 with the two lowest doses of both
test and reference product (one and two actuations), as
recommended above, to estimate with sensitivity the
potency of the new pMDI plus spacer in comparison to the
reference DPI. It is important to remember that studies
similar to the present one involving a larger number of
patients and for a longer duration would be equally
insensitive. In fact, to estimate the relative potency of
bronchodilator agents, a single-dose study is enough. This
does not mean that long-term studies are not required for
this product. In this case, a long-term safety study would be
necessary to investigate the safety and tolerability profile of
the mixture of drug and excipients employed in this new
pMDI, since it cannot be claimed to be similar to another one
in the market. However, the comparison of the safety profile
of both products due to the systemic exposure to tiotropium
after oral, if any, and pulmonary absorption could be carried
out in a conventional pharmacokinetic bioequivalence study,
since plasma concentrations of tiotropium can be de-
tected.17 In addition, this pharmacokinetic study would be
very informative because AUC would indicate the amount of
drug reaching the lungs, since the fraction absorbed through
the gastrointestinal tract seem to be negligible for
quaternary ammonium compounds, and Cmax provide in-
formation on the pattern of deposition.18–20
This represents the personal opinion of the author and
does not necessarily represent the views or policy of the
Spanish Agency for Medicines and Health Care Products.References
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